Vaximm seeks pharma partners for T-cell/checkpoint inhibitor combos

December 16, 2016 Christoph Graener

 

Dr. Matthias Schroff, the new CEO of privately-held Swiss vaccines company Vaximm, talks to Mike Ward, global director of content for Informa Pharma Intelligence, about how the company is differentiating itself in the crowded immuno-oncology development space. Vaximm is also looking for pharma partners with checkpoint inhibitors to advance its oral T-cell immunotherapies.
The company’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be adapted to target a wide range of cancer-related antigens. Vaximm’s most advanced compound, VXM01, is in Phase I/IIa studies with data expected in early 2017.
Schroff was appointed CEO of Vaximm in September this year; previously he was CEO of Mologen AG, a publicly-traded German biotech company.

  

  

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Dr. Matthias Schroff – CEO, VAXIMM

 

Previous Article
Atlantic Healthcare outlines filing plans
Atlantic Healthcare outlines filing plans

CEO Toby Wilson Waterworth of Atlantic Healthcare discusses the company's recent fundraising and outlines A...

Next Article
How are regulatory changes affecting early stage R&D in China?
How are regulatory changes affecting early stage R&D in China?

Darren Ji discusses the recent crackdown on clinical data quality by the China FDA and regulatory changes f...